3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
35
Carcinoma, Non-Small-Cell Lung
17
Small Cell Lung Carcinoma
16
Neoplasms
14
Lung Neoplasms
13
Breast Neoplasms
7
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Liver Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Glioblastoma
4
Endometrial Neoplasms
4
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Carcinoma, Transitional Cell
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Ovarian Neoplasms
2
Osteosarcoma
2
Mesothelioma, Malignant
2
Mesothelioma
2
Interventions
Liver Transplantation
2
Blood Specimen Collection
2
esmolol
1
atezolizumab
1
apixaban
1
User-Centered Design
1
Tocopherols
1
Standard of Care
1
Sampling Studies
1
Pravastatin
1
Pharmaceutical Preparations
1
Pentoxifylline
1
Neuropsychological Tests
1
Memantine
1
Losartan
1
Ketoprofen
1
Enoxaparin
1
Endoscopy, Digestive System
1
Diagnostic Imaging
1
Bevacizumab
1
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fibrosis
×
atezolizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled